Oncology
6th Annual Gulf-Atlantic Veterinary Conference
Chad Johannes, DVM, DACVIM (SAIM, Oncology)
Iowa State University
Treatment of dogs with osteosarcoma (OSA) remains incredibly challenging with long-term (> 2 year) survival rates of only 10-15 percent. While current adjuvant therapy protocols have improved the survival time of dogs diagnosed with OSA compared to dogs receiving amputation alone, there has been no significant improvement in long-term outcomes in the last 15 to 20 years. With the therapeutic plateau being seemingly reached for dogs with OSA utilizing current options, development of alternate or complementary adjuvant therapies for treating local and micrometastatic disease is needed. This session will highlight clinical integration of stereotactic radiation therapy and the canine osteosarcoma vaccine, live listeria vector (AT-014), in dogs with OSA via case examples.